Aptevo Therapeutics (APVO) Price & Analysis

Q: What was Aptevo Therapeutics Inc’s price range in the past 12 months?

Aptevo Therapeutics Inc lowest stock price was $1.32 and its highest was $381.75 in the past 12 months.

Q: What is Aptevo Therapeutics Inc’s market cap?

Aptevo Therapeutics Inc’s market cap is $22.37M.

Q: When is Aptevo Therapeutics Inc’s upcoming earnings report date?

Aptevo Therapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 15 days.

Q: How were Aptevo Therapeutics Inc’s earnings last quarter?

Aptevo Therapeutics Inc released its earnings results on Aug 11, 2025. The company reported -$8.4 earnings per share for the quarter, beating the consensus estimate of -$83.2 by $74.8.

Q: Is Aptevo Therapeutics Inc overvalued?

According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Aptevo Therapeutics Inc pay dividends?

Aptevo Therapeutics Inc does not currently pay dividends.

Q: What is Aptevo Therapeutics Inc’s EPS estimate?

Aptevo Therapeutics Inc’s EPS estimate is -2.09.

Q: How many shares outstanding does Aptevo Therapeutics Inc have?

Aptevo Therapeutics Inc has 13,808,966 shares outstanding.

Q: What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?

Aptevo Therapeutics Inc reported an EPS of -$8.4 in its last earnings report, beating expectations of -$83.2. Following the earnings report the stock price went down -4.867%.

Q: Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?

Currently, no hedge funds are holding shares in APVO

Compare

707 Followers

APVO Stock Chart & Stats

$1.57

-$0.30(-5.81%)

At close: Jan 08 4:00 PM EST

$1.57

-$0.30(-5.81%)

Day’s Range― - ―

52-Week Range$1.32 - $381.75

Previous CloseN/A

Volume25.11K

Average Volume (3M)11.64M

Market Cap

$22.37M

Enterprise Value-$2.95M

Total Cash (Recent Filing)$9.41M

Total Debt (Recent Filing)$4.21M

Price to Earnings (P/E)―

Beta-0.43

Next Earnings

Nov 06, 2025

EPS Estimate

-2.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-8.40

Shares Outstanding13,808,966

10 Day Avg. Volume7,942,705

30 Day Avg. Volume11,635,265

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.25

Price to Sales (P/S)0.00

P/FCF Ratio-0.05

Enterprise Value/Market Cap-0.13

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit12.55

Enterprise Value/Ebitda0.12

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering0

Aptevo Therapeutics News

Aptevo Therapeutics files to sell 6.9M shares of common stock for holders

16:33 EDT Aptevo Therapeutics (APVO) files to sell 6.9M shares of common stock for holders Published first on...

21d ago

APVO

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Earnings reports, lawsuits, investments, and more make up the top stock market stories worth reading on Thursday. ...

1M ago

AMD

AXP

Why Is Aptevo Therapeutics Stock (APVO) Up 85% Today?

Aptevo Therapeutics stock rallied on Thursday after it revealed a large investment from Point72 Asset Management, L.P. ...

1M ago

APVO

Aptevo Announces 100% Remission in AML Trial

Aptevo Therapeutics ( ($APVO) ) just unveiled an announcement. On September 16, 2025, Aptevo Therapeutics announced a 100%...

1M ago

APVO

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

TipRanks has collected the top stock market headlines traders need to read on Tuesday. ...

1M ago

AMD

Why Is Aptevo Therapeutics Stock (APVO) Up 50% Today?

Aptevo Therapeutics stock surged on Tuesday alongside positive clinical trial results. ...

1M ago

APVO

Aptevo says mipletamig deliver 100% remission rate in RAINIER cohort 3

Aptevo Therapeutics (APVO) announced a 100% remission rate in Cohort 3 of its Phase 1b/2 RAINIER trial evaluating...

1M ago

APVO

Aptevo Therapeutics Expands Anti-Cancer Pipeline with Patents

Aptevo Therapeutics ( ($APVO) ) just unveiled an update. On September 4, 2025, Aptevo Therapeutics announced the expansion...

2M ago

APVO

Aptevo Therapeutics expands anti-cancer pipeline with APVO452, APVO451

Aptevo Therapeutics (APVO) announced expansion of its anti-cancer pipeline with the filing of two provisional patents for trispecific...

2M ago

APVO

Aptevo Therapeutics highlights APVO442 preclinical candidate for prostate cancer

Aptevo Therapeutics (APVO) reinforced the strategic importance of its preclinical asset APVO442-an investigational CD3-engaging bispecific antibody designed to...

2M ago

APVO

Aptevo Therapeutics reports Q2 EPS ($8.40) vs. ($1,236.96) last year

“The second quarter marked a period of decisive progress for Aptevo across both clinical and corporate fronts,” said...

2M ago

APVO

Aptevo Therapeutics files to sell 8.25M shares of common stock for holders

16:17 EDT Aptevo Therapeutics (APVO) files to sell 8.25M shares of common stock for holders Published first on...

3M ago

APVO

Aptevo Therapeutics Holds Annual Stockholders Meeting

Aptevo Therapeutics ( ($APVO) ) has shared an announcement. On July 24, 2025, Aptevo Therapeutics Inc. held its...

3M ago

APVO

Aptevo Therapeutics Regains Nasdaq Compliance with Equity Raise

Aptevo Therapeutics ( ($APVO) ) has provided an update. Aptevo Therapeutics Inc. announced that it has regained compliance...

4M ago

APVO

APVO FAQ

What was Aptevo Therapeutics Inc’s price range in the past 12 months?

Aptevo Therapeutics Inc lowest stock price was $1.32 and its highest was $381.75 in the past 12 months.

What is Aptevo Therapeutics Inc’s market cap?

Aptevo Therapeutics Inc’s market cap is $22.37M.

When is Aptevo Therapeutics Inc’s upcoming earnings report date?

Aptevo Therapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 15 days.

How were Aptevo Therapeutics Inc’s earnings last quarter?

Aptevo Therapeutics Inc released its earnings results on Aug 11, 2025. The company reported -$8.4 earnings per share for the quarter, beating the consensus estimate of -$83.2 by $74.8.

Is Aptevo Therapeutics Inc overvalued?

According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Aptevo Therapeutics Inc pay dividends?

Aptevo Therapeutics Inc does not currently pay dividends.

What is Aptevo Therapeutics Inc’s EPS estimate?

Aptevo Therapeutics Inc’s EPS estimate is -2.09.

How many shares outstanding does Aptevo Therapeutics Inc have?

Aptevo Therapeutics Inc has 13,808,966 shares outstanding.

What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?

Aptevo Therapeutics Inc reported an EPS of -$8.4 in its last earnings report, beating expectations of -$83.2. Following the earnings report the stock price went down -4.867%.

Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?

Currently, no hedge funds are holding shares in APVO

Company Description

Aptevo Therapeutics Inc

Aptevo Therapeutics (APVO) is a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics aimed at providing innovative treatments for cancer and other life-threatening diseases. The company operates primarily in the biotechnology and pharmaceutical sectors, leveraging its proprietary ADAPTIR and ADAPTIR-FLEX platforms to create bispecific antibody therapeutics. Aptevo's core products include APVO436, a bispecific antibody candidate targeting acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), among other developmental candidates.